Advertisment

Biotechnology Innovation Organization Welcomes John Crowley as New CEO

author-image
Dr. Jessica Nelson
New Update
NULL

Biotechnology Innovation Organization Welcomes John Crowley as New CEO

Advertisment

The Biotechnology Innovation Organization (BIO), the world's largest biotechnology policy and advocacy association, recently announced a significant change in its leadership. Effective March 4, 2024, John Crowley will assume the role of President and Chief Executive Officer. This appointment has drawn considerable attention within the biotechnology industry due to Crowley's unique background and significant contributions in the field of rare diseases.

Advertisment

John Crowley: A Rare Disease Advocate

Crowley's journey into the biotech industry is deeply personal. After his children were diagnosed with a rare genetic neuromuscular disease, Crowley dedicated his career to advancing therapies for rare diseases. His involvement in the development of enzyme replacement therapy for Pompe disease, a rare inherited disorder affecting the muscles and nerves, has been instrumental in improving treatment options for patients.

Crowley's Contributions to Amicus Therapeutics

Advertisment

Prior to his appointment at BIO, Crowley served as Executive Chairman of Amicus Therapeutics. He joined Amicus in 2005 and held the position of Chairman and Chief Executive Officer until 2022. Under Crowley's leadership, Amicus transformed from an early-stage start-up into a multi-billion dollar, publicly traded, commercial organization. Today, the company boasts two marketed therapies and a workforce of over 500 employees across 21 countries worldwide. These therapies are currently being used to treat thousands of individuals living with rare and devastating diseases.

The Biotechnology Innovation Organization's New Direction

As the newly appointed CEO of BIO, Crowley will lead an organization that represents over 1,200 member organizations worldwide. BIO is based in Washington, DC, and serves as the world's largest biotechnology policy and advocacy association. The trade association's board chair, Ted Love, who has connections to Amicus, expressed enthusiasm about Crowley's appointment.

With Crowley's proven track record in the biotech industry and his personal commitment to advancing therapies for rare diseases, the biotechnology community awaits the new direction BIO will take under his leadership. His appointment is a reminder of the critical role biotechnology plays in addressing unmet medical needs and improving the lives of patients around the world.

Advertisment
Chat with Dr. Medriva !